作者: Ramamoorthy Nagasubramanian , Julie Wei , Paul Gordon , Jeff C. Rastatter , Michael C. Cox
DOI: 10.1002/PBC.26026
关键词:
摘要: Infantile fibrosarcoma (IFS) is a rare pediatric cancer typically presenting in the first 2 years of life. Surgical resection usually curative and chemotherapy active against gross residual disease. However, when recurrences occur, therapeutic options are limited. We report case refractory IFS with constitutive activation tropomyosin-related kinase (TRK) signaling pathway from an ETS variant gene 6-neurotrophin 3 receptor (ETV6-NTRK3) fusion. The patient enrolled Phase 1 trial LOXO-101, experimental, highly selective inhibitor TRK. experienced rapid, radiographic response, demonstrating potential for LOXO-101 to provide benefit harboring NTRK fusions.